Menu
Recruiting NCT07579845

Clinical Trial Evaluating the Impact of a Dietary Supplement Containing Humic and Fulvic Acid on Epigenetic Markers of Biological Age, Detoxification, Inflammation, and Oxidative Stress

No phase Interventional Detoxification Inflammation Biological Aging

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Humic and Fulvic Acid Dietary Supplement.
Who it may be relevant to
Registry conditions: Detoxification, Inflammation, Biological Aging. Basic parameters: from 40 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The primary purpose of this study is to evaluate the impact of BioToxin Binder, a commercially available dietary supplement containing humic and fulvic acid, on markers of biologic age, detoxification, inflammation, oxidative stress, and related markers among generally healthy adults.

Interventions

  • Dietary supplement Humic and Fulvic Acid Dietary Supplement
    BioToxin Binder (CellCore Biosciences, Palm Beach Gardens, FL) - Humic and Fulvic Acid Dietary Supplement

Primary outcome measures

  • TruDiagnostic - Epigenetic Testing [Time frame: Change in TruAge from baseline to 12 weeks]

Eligibility criteria

Inclusion criteria

  • Adult females or males age ≥ 40 years
  • Ability to read and speak English

Exclusion criteria

  • Current use of a dietary supplement containing fulvic or humic acid
  • Current use of other binder dietary supplements, including activated charcoal, modified citrus pectin, bentonite clay, or chlorella
  • Known allergies to any ingredients in the product
  • Currently pregnant or lactating women or women planning to become pregnant in the next 12 weeks
  • Current diagnosis of a chronic health condition (e.g., cancer, heart failure, history of pancreatitis, type I or II diabetics on insulin) deemed clinically contraindicated for the study protocol
  • Participants unable to provide consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

United States · 1 center
  • OvationLab — Richmond

Identifiers

NCT: NCT07579845 · CC-001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗